Accelerating cocaine metabolism as an approach to the treatment of cocaine abuse and toxicity

Future Medicinal Chemistry

Volumn 4, Issue 2, 2012, Pages 163-175

  Schindler, Charles W ^a   Goldberg, Steven R ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Primary enzyme responsible for the metabolism of cocaine in humans

Indexed keywords

CHOLINESTERASE; COCAINE; MONOCLONAL ANTIBODY; PROTEIN C FOS;

ARTICLE; BLOOD PRESSURE; CATALYSIS; COCA; DRUG ABUSE; DRUG HALF LIFE; DRUG TOXICITY; GENE MUTATION; HUMAN; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BUTYRYLCHOLINESTERASE; CARBOXYLIC ESTER HYDROLASES; COCAINE; COCAINE-RELATED DISORDERS; HUMANS; MUTATION;

EID: 84856812621     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.11.181     Document Type: Article

References (92)

1. Substance Abuse and Mental Health Administration. Drug Abuse Warning Network, 2008: National Estimates of Drug-Related Emergency Department Visits. HHS Publication No. SMA 11-4618, Rockville, MD, USA (2011).
2. Kampman KM. What's new in the treatment of cocaine addiction? Curr. Psychiatry Rep. 12(5), 441-447 (2010).
3. Karila L, Gorelick D, Weinstein A et al. New treatments for cocaine dependence: a focused review. Int. J. Neuropsychopharmacology 11(3), 425-438 (2008). (Pubitemid 351482505)
4. Penberthy JK, Ait-Daoud N, Vaughan M, Fanning T. Review of treatment for cocaine dependence. Curr. Drug Abuse Rev. 3(1), 49-62 (2010).
5. Fox BS, Kantak KM, Edwards MA et al. Efficacy of a therapeutic cocaine vaccine in rodent models. Nat. Med. 2(10), 1129-1132 (1996). (Pubitemid 26338633)
6. Carrera MR, Ashley JA, Zhou B, Wirsching P, Koob GF, Janda KD. Cocaine vaccines: antibody protection against relapse in a rat model. Proc. Natl Acad. Sci. USA 97(11), 6202-6206 (2000). (Pubitemid 30367547)
7. Kantak KM, Collins SL, Lipman EG, Bond J, Giovanoni K, Fox BS. Evaluation of anticocaine antibodies and a cocaine vaccine in a rat self-administration model. Psychopharmacology 148(3), 251-262 (2000). (Pubitemid 30136732)
8. Kosten TR, Rosen M, Bond J et al. Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine 20(7-8), 1196-1204 (2002). (Pubitemid 34135957)
9. Haney M, Gunderson EW, Jiang H, Collins ED, Foltin RW. Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans. Biol. Psychiatry 67(1), 59-65 (2010).
10. Martell BA, Orson FM, Poling J et al. Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double blind, placebo-controlled efficacy trial. Arch. Gen. Psychiatry 66(10), 1116-1123 (2009).
11. Hicks MJ, De BP, Rosenberg JB et al. Cocaine analog coupled to disrupted adenovirus: a vaccine strategy to evoke high-titer immunity against addictive drugs. Mol. Ther. 19(3), 612-619 (2011).
12. Norman AB, Tabet MR, Norman MK, Buesing WR, Pesce AJ, Ball WJ. A chimeric human/murine anticocaine monoclonal antibody inhibits the distribution of cocaine to the brain in mice. J. Pharmacol. Exp. Ther. 320(1), 145-153 (2007). (Pubitemid 46025729)
13. Norman A, Norman M, Buesing W, Tabet M, Tsibulsky V, Ball W. The effect of a chimeric human/murine anticocaine monoclonal antibody on cocaine self-administration in rats. J. Pharmacol. Exp. Ther. 328(3), 873-881 (2008).
14. Kinsey BM, Kosten TR, Orson FM. Anticocaine vaccine development. Expert Rev. Vaccines 9(9), 1109-1114 (2010).
15. Gorelick DA. Pharmacokinetic approaches to treatment of drug addiction. Expert Rev. Clin. Pharmacol. 1(2), 277-290 (2008).
16. Inaba T, Stewart DJ, Kalow W. Metabolism of cocaine in man. Clin. Pharmacol. Ther. 23(5), 547-552 (1978). (Pubitemid 8347677)
17. Stewart DJ, Inaba T, Tang BK, Kalow W. Hydrolysis of cocaine in human plasma by cholinesterase. Life Sci. 20(9), 1557-1563 (1977). (Pubitemid 8118362)
18. Carmona GN, Baum I, Schindler CW et al. Plasma butyrylcholinesterase activity and cocaine half-life differ significantly in rhesus and squirrel monkeys. Life Sci. 59(11), 939-943 (1996). (Pubitemid 26264462)
19. Devenyi P. Cocaine complications and pseudocholinesterase. Ann. Intern. Med. 110(2), 167-168 (1989).
20. Hoffman RS, Henry GC, Howland MA, Weisman RS, Weil L, Goldfrank LR. Association between life-threatening cocaine toxicity and plasma cholinesterase activity. Ann. Emerg. Med. 21(3), 247-253 (1992).
21. Jatlow P, Barash PG, Van Dyke C, Radding J, Byck R. Cocaine and succinylcholine sensitivity: a new caution. Anesth. Analg. 58(3), 235-238 (1979). (Pubitemid 9188773)
22. Om A, Ellahham S, Ornato JP et al. Medical complications of cocaine: possible relationship to low plasma cholinesterase enzyme. Am. Heart J. 125(4), 1114-1117 (1993). (Pubitemid 23117346)
23. Morishima HO, Abe Y, Matsuo M, Akiba K, Masaoka T, Cooper TB. Gender-related differences in cocaine toxicity in the rat. J. Lab. Clin. Med. 122(2), 157-163 (1993). (Pubitemid 23239146)
24. Hoffman RS, Morasco R, Goldfrank LR. Administration of purified human plasma cholinesterase protects against cocaine toxicity in mice. J. Toxicol. Clin. Toxicol. 34(3), 259-266 (1996). (Pubitemid 26198099)
25. Duysen EG, Li B, Carlson M et al. Increased hepatotoxicity and cardiac fibrosis in cocaine-treated butyrylcholinesterase knockout mice. Basic Clin. Pharmacol. Toxicol. 103(6), 514-521 (2008).
26. Herschman Z, Aaron C. Prolongation of cocaine effect. Anesthesiology 74(3), 631-632 (1991).
27. Schuelke GS, Konkol RJ, Terry LC, Madden JA. Effect of cocaine metabolites on behavior: possible neuroendocrine mechanisms. Brain Res. Bull. 39(1), 43-48 (1996). (Pubitemid 26002146)
28. Landry DW, Zhao K, Yang GX, Glickman M, Georgiadis TM. Antibody-catalyzed degradation of cocaine. Science 259(5103), 1899-1901 (1993). (Pubitemid 23124461)
29. Gorelick DA. Enhancing cocaine metabolism with butyrylcholinesterase as a treatment strategy. Drug Alcohol Depend. 48(3), 159-165 (1997). (Pubitemid 27526022)
30. Sun H, El Yazal J, Lockridge O, Schopfer LM, Brimijoin S, Pang YP. Predicted Michaelis-Menten complexes of cocaine-butyrylcholinesterase. Engineering effective butyrylcholinesterase mutants for cocaine detoxication. J. Biol. Chem. 276(12), 9330-9336 (2001).
31. Bresler MM, Rosser SJ, Basran A, Bruce NC. Gene cloning and nucleotide sequencing and properties of a cocaine esterase from Rhodococcus sp. strain MB1. Appl. Environ. Microbiol. 66(3), 904-908 (2000). (Pubitemid 30130004)
32. Tramontano A, Janda KD, Lerner RA. Catalytic antibodies. Science 234(4783), 1566-1570 (1986). (Pubitemid 17125281)
33. Yang G, Chun J, Arakawa-Uramoto H et al. Anticocaine catalytic antibodies: a synthetic approach to improved antibody diversity. J. Am. Chem. Soc. 118, 5881-5890 (1996). (Pubitemid 26236808)
34. Mets B, Winger G, Cabrera C et al. A catalytic antibody against cocaine prevents cocaine's reinforcing and toxic effects in rats. Proc. Natl Acad. Sci. USA 95(17), 10176-10181 (1998). (Pubitemid 28415314)
35. Baird TJ, Deng SX, Landry DW, Winger G, Woods JH. Natural and artificial enzymes against cocaine. I. Monoclonal antibody 15A10 and the reinforcing effects of cocaine in rats. J. Pharmacol. Exp. Ther. 295(3), 1127-1134 (2000).
36. Briscoe RJ, Jeanville PM, Cabrera C, Baird TJ, Woods JH, Landry DW. A catalytic antibody against cocaine attenuates cocaine's cardiovascular effects in mice: a dose and time course analysis. Int. Immunopharmacol. 1(6), 1189-1198 (2001). (Pubitemid 32434434)
37. Deng S, Bharat N, de Prada P, Landry DW. Substrate-assisted antibody catalysis. Org. Biomol. Chem. 2(3), 288-290 (2004).
38. Isomura S, Hoffman TZ, Wirsching P, Janda KD. Synthesis, properties, and reactivity of cocaine benzoylthio ester possessing the cocaine absolute configuration. J. Am. Chem. Soc. 124(14), 3661-3668 (2002). (Pubitemid 34407890)
39. Matsushita M, Hoffman TZ, Ashley JA, Zhou B, Wirsching P, Janda KD. Cocaine catalytic antibodies: the primary importance of linker effects. Bioorg. Med. Chem. Lett. 11(2), 87-90 (2001). (Pubitemid 32099616)
40. Zhu X, Dickerson TJ, Rogers CJ et al. Complete reaction cycle of a cocaine catalytic antibody at atomic resolution. Structure 14(2), 205-216 (2006). (Pubitemid 43202010)
41. McKenzie KM, Mee JM, Rogers CJ, Hixon MS, Kaufmann GF, Janda KD. Identification and characterization of single chain anticocaine catalytic antibodies. J. Mol. Biol. 365(3), 722-731 (2007). (Pubitemid 44960359)
42. Cashman JR, Berkman CE, Underiner GE. Catalytic antibodies that hydrolyze (-)-cocaine obtained by a high-throughput procedure. J. Pharmacol. Exp. Ther. 293(3), 952-961 (2000). (Pubitemid 30417863)
43. Ashani Y, Shapira S, Levy D, Wolfe AD, Doctor BP, Raveh L. Butyrylcholinesterase and acetylcholinesterase prophylaxis against soman poisoning in mice. Biochem. Pharmacol. 41(1), 37-41 (1991).
44. Brandeis R, Raveh L, Grunwald J, Cohen E, Ashani Y. Prevention of soman-induced cognitive deficits by pretreatment with human butyrylcholinesterase in rats. Pharmacol. Biochem. Behav. 46(4), 889-896 (1993).
45. Doctor BP, Raveh L, Wolfe AD, Maxwell DM, Ashani Y. Enzymes as pretreatment drugs for organophosphate toxicity. Neurosci. Biobehav. Rev. 15(1), 123-128 (1991).
46. Wolfe AD, Blick DW, Murphy MR et al. Use of cholinesterases as pretreatment drugs for the protection of rhesus monkeys against soman toxicity. Toxicol. Appl. Pharmacol. 117(2), 189-193 (1992). (Pubitemid 23009714)
47. Huang Y-J, Huang Y, Baldassarre H et al. Recombinant human butyrylcholinesterase from milk of transgenic animals to protect against organophosphate poisoning. Proc. Natl Acad. Sci. USA 104(34), 13603-13608 (2007). (Pubitemid 350010655)
48. Lockridge O, Schopfer LM, Winger G, Woods JH. Large scale purification of butyrylcholineserase from human plasma suitable for injection into monkeys: a potential new therapeutic for protection against cocaine and nerve agent toxicity. J. Med. Chem. Biol. Radiol. Def. 3, nihms5095 (2005).
49. Mattes CE, Lynch TJ, Singh A et al. Therapeutic use of butyrylcholinesterase for cocaine intoxication. Toxicol. Appl. Pharmacol. 145(2), 372-380 (1997).
50. Browne SP, Slaughter EA, Couch RA, Rudnic EM, McLean AM. The influence of plasma butyrylcholinesterase concentration on the in vitro hydrolysis of cocaine in human plasma. Biopharm. Drug Dispos. 19(5), 309-314 (1998). (Pubitemid 28313930)
51. Carmona GN, Schindler CW, Shoaib M et al. Attenuation of cocaine-induced locomotor activity by butyrylcholinesterase. Exp. Clin. Psychopharmacol. 6(3), 274-279 (1998). (Pubitemid 28393945)
52. Carmona GN, Schindler CW, Greig NH et al. Intravenous butyrylcholinesterase administration and plasma and brain levels of cocaine and metabolites in rats. Eur. J. Pharmacol. 517(3), 186-190 (2005). (Pubitemid 40977894)
53. Koetzner L, Woods JH. Characterization of butyrylcholinesterase antagonism of cocaine-induced hyperactivity. Drug Metab. Dispos. 30(6), 716-723 (2002). (Pubitemid 34579107)
54. Lynch TJ, Mattes CE, Singh A, Bradley RM, Brady RO, Dretchen KL. Cocaine detoxification by human plasma butyrylcholinesterase. Toxicol. Appl. Pharmacol. 145(2), 363-371 (1997). (Pubitemid 27346526)
55. Duysen EG, Bartels CF, Lockridge O. Wild-type and A328W mutant human butyrylcholinesterase tetramers expressed in Chinese hamster ovary cells have a 16-hour half-life in the circulation and protect mice from cocaine toxicity. J. Pharmacol. Exp. Ther. 302(2), 751-758 (2002). (Pubitemid 34787244)
56. Zheng F, Yang W, Ko M-C et al. Most efficient cocaine hydrolase designed by virtual screening of transition states. J. Am. Chem. Soc. 130(36), 12148-12155 (2008).
57. Sun H, Pang Y-P, Lockridge O, Brimijoin S. Re-engineering butyrylcholinesterase as a cocaine hydrolase. Mol. Pharmacol. 62(2), 220-224 (2002). (Pubitemid 34804100)
58. Sun H, Shen ML, Pang Y-P, Lockridge O, Brimijoin S. Cocaine metabolism accelerated by a re-engineered human butyrylcholinesterase. J. Pharmacol. Exp. Ther. 302(2), 710-716 (2002). (Pubitemid 34787239)
59. Gao Y, Brimijoin S. An engineered cocaine hydrolase blunts and reverses cardiovascular responses to cocaine in rats. J. Pharmacol. Exp. Ther. 310(3), 1046-1052 (2004). (Pubitemid 39108926)
60. Gao Y, Lafleur D, Shah R, Zhao Q, Singh M, Brimijoin S. An albumin-butyrylcholinesterase for cocaine toxicity and addiction: catalytic and pharmacokinetic properties. Chem. Biol. Interact. 175(1-3), 83-87 (2008).
61. Pancock JD, Pecht G, Mosko M, Lockridge O, Watkins JD. Application of directed evolution technology to optimize the cocaine hydrolase activity of human butyrylcholinesterase. FASEB J. 17, A565 (2003).
62. Gao Y, Atanasova E, Sui N, Pancook JD, Watkins JD, Brimijoin S. Gene transfer of cocaine hydrolase suppresses cardiovascular responses to cocaine in rats. Mol. Pharmacol. 67(1), 204-211 (2005). (Pubitemid 40069980)
63. Yang W, Xue L, Fang L, Chen X, Zhan C-G. Characterization of a high-activity mutant of human butyrylcholinesterase against (-)-cocaine. Chem. Biol. Interact. 187(1-3), 148-152 (2010).
64. Gao Y, Orson FM, Kinsey B, Kosten T, Brimijoin S. The concept of pharmacologic cocaine interception as a treatment for drug abuse. Chem. Biol. Interact. 187(1-3), 421-424 (2010).
65. Schindler CW, Justinova Z, Lafleur D et al. Modification of pharmacokinetic and abuse-related effects of cocaine by human-derived cocaine hydrolase in monkeys. Addiction Biology (2011) (In press).
66. Brimijoin S, Gao Y, Anker JJ et al. A cocaine hydrolase engineered from human butyrylcholinesterase selectively blocks cocaine toxicity and reinstatement of drug seeking in rats. Neuropsychopharmacology 33(11), 2715-2725 (2008).
67. Carroll ME, Gao Y, Brimijoin S, Anker JJ. Effects of cocaine hydrolase on cocaine self-administration under a PR schedule and during extended access (escalation) in rats. Psychopharmacology 213(4), 817-829 (2011).
68. Xue L, Ko M-C, Tong M et al. Design, preparation and characterization of high-activity mutants of human butyrylcholinesterase specific for detoxification of cocaine. Mol. Pharmacol. 79(2), 290-297 (2011).
69. Gao Y, Brimijoin S. Viral transduction of cocaine hydrolase in brain reward centers. Cell. Mol. Neurobiol. 26(4-6), 357-363 (2006).
70. Gao Y, Brimijoin S. Lasting reduction of cocaine action in neostriatum - a hydrolase gene therapy approach. J. Pharmacol. Exp. Ther. 330(2), 449-457 (2009).
71. Parikh K, Duysen EG, Snow B et al. Gene-delivered butyrylcholinesterase is prophylactic against the toxicity of chemical warfare nerve agents and organophosphorus compounds. J. Pharmacol. Exp. Ther. 337(1), 92-101 (2011).
72. Cooper ZD, Narasimhan D, Sunahara RK et al. Rapid and robust protection against cocaine-induced lethality in rats by the bacterial cocaine esterase. Mol. Pharmacol. 70(6), 1885-1891 (2006). (Pubitemid 44771904)
73. Larsen NA, Turner JM, Stevens J et al. Crystal structure of a bacterial cocaine esterase. Nat. Struct. Biol. 9(1), 17-21 (2002). (Pubitemid 34049173)
74. Turner JM, Larsen NA, Basran A et al. Biochemical characterization and structural analysis of a highly proficient cocaine esterase. Biochemistry 41(41), 12297-12307 (2002).
75. Ko M-C, Bowen LD, Narasimhan D et al. Cocaine esterase: interactions with cocaine and immune responses in mice. J. Pharmacol. Exp. Ther. 320(2), 926-933 (2007). (Pubitemid 46147977)
76. Ko M-C, Narasimhan D, Berlin AA, Lukacs NW, Sunahara RK, Woods JH. Effects of cocaine esterase following its repeated administration with cocaine in mice. Drug Alcohol Depend. 101(3), 202-209 (2009).
77. Jutkiewicz EM, Baladi MG, Cooper ZD, Narasimhan D, Sunahara RK, Woods JH. A bacterial cocaine esterase protects against cocaine-induced epileptogenic activity and lethality. Ann. Emerg. Med. 54(3), 409-420 (2009).
78. Wood SK, Narasimhan D, Cooper Z, Sunahara RK, Woods JH. Prevention and reversal by cocaine esterase of cocaine-induced cardiovascular effects in rats. Drug Alcohol Depend. 106(2-3), 219-229 (2010).
79. Narasimhan D, Nance MR, Gao D et al. Structural analysis of thermostabilizing mutations of cocaine esterase. Protein Eng. Des. Sel. 23(7), 537-547 (2010).
80. Collins GT, Brim RL, Narasimhan D et al. Cocaine esterase prevents cocaine-induced toxicity and the ongoing intravenous self-administration of cocaine in rats. J. Pharmacol. Exp. Ther. 331(2), 445-455 (2009).
81. Collins GT, Zaks ME, Cunningham AR et al. Effects of a long-acting mutant bacterial cocaine esterase on acute cocaine toxicity in rats. Drug Alcohol Depend. 118, 158-165 (2011).
82. Collins GT, Carey KA, Narasimhan D et al. Amelioration of the cardiovascular effects of cocaine in rhesus monkeys by a long-acting mutant form of cocaine esterase. Neuropsychopharmacology 36(5), 1047-1059 (2011).
83. Brim RL, Nance MR, Youngstrom DW et al. A thermally stable form of bacterial cocaine esterase: a potential therapeutic agent for treatment of cocaine abuse. Mol. Pharmacol. 77(4), 593-600 (2010).
84. Genovese RF, Sun W, Johnson CC, Ditargiani RC, Doctor BP, Saxena A. Safety of administration of human butyrylcholinesterase and its conjugates with soman or VX in rats. Basic Clin. Pharmacol. Toxicol. 106(5), 428-434 (2010).
85. Rogers CJ, Mee JM, Kaufmann GF, Dickerson TJ, Janda KD. Toward cocaine esterase therapeutics. J. Am. Chem. Soc. 127(28), 10016-10017 (2005). (Pubitemid 40995442)
86. Collins GT, Narasimhan D, Cunningham AR et al. Long-lasting effects of a PEGylated mutant cocaine esterase (CocE) on the reinforcing and discriminative stimulus effects of cocaine in rats. Neuropsychopharmacology doi:10.1038/ npp.2011.226 (2011) (Epub ahead of print).
87. Brim RL, Noon KR, Nichols J, Narasimhan D, Woods JH, Sunahara RK. Evaluation of the hydrolytic activity of a long-acting mutant bacterial cocaine in the presence of commonly co-administered drugs. Drug Alcohol Depend. 119(3), 224-228 (2011).
88. Caine SB, Koob GF. Effects of dopamine D-1 and D-2 antagonists on cocaine self-administration under different schedules of reinforcement in the rat. J. Pharmacol. Exp. Ther. 270(1), 209-218 (1994). (Pubitemid 24229630)
89. Sparenborg S, Vocci F, Zukin S. Peripheral cocaine-blocking agents: new medications for cocaine dependence. An introduction to immunological and enzymatic approaches to treating cocaine dependence reported by Fox, Gorelick and Cohen in the immediately succeeding articles (see pages 153-174). Drug Alcohol Depend. 48(3), 149-151 (1997). (Pubitemid 27526020)
90. Mattes C, Bradley R, Slaughter E, Browne S. Cocaine and butyrylcholinesterase (BChE): determination of enzymatic parameters. Life Sci. 58(13), PL257-261 (1996). (Pubitemid 26086425)
91. Xie W, Altamirano CV, Bartels CF, Speirs RJ, Cashman JR, Lockridge O. An improved cocaine hydrolase: the A328Y mutant of human butyrylcholinesterase is 4-fold more efficient. Mol. Pharmacol. 55(1), 83-91 (1999). (Pubitemid 29042525)
92. Carmona GN, Jufer RA, Goldberg SR et al. Butyrylcholinesterase accelerates cocaine metabolism: in vitro and in vivo effects in nonhuman primates and humans. Drug Metab. Dispos. 28(3), 367-371 (2000). (Pubitemid 30137064)